GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Forward Rate of Return (Yacktman) %

NXEN (Nexien BioPharma) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Nexien BioPharma's forward rate of return for was 0.00%.

The historical rank and industry rank for Nexien BioPharma's Forward Rate of Return (Yacktman) % or its related term are showing as below:

NXEN's Forward Rate of Return (Yacktman) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.22
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Nexien BioPharma Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Nexien BioPharma's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma Forward Rate of Return (Yacktman) % Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial - - - - -

Nexien BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nexien BioPharma's Forward Rate of Return (Yacktman) %

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexien BioPharma's Forward Rate of Return (Yacktman) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's Forward Rate of Return (Yacktman) % falls into.


;
;

Nexien BioPharma Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Nexien BioPharma's Forward Rate of Return of Dec. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.0056+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexien BioPharma  (OTCPK:NXEN) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Nexien BioPharma Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexien BioPharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is a U.S.-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration ('FDA') pre-clinical and clinical pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108